Eton Pharmaceuticals, Inc. (NASDAQ: ETON) Stock Competitors & Peer Comparison

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, TAK has a market cap of 57.2B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while TAK trades at $18.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas TAK's P/E ratio is 12.93. In terms of profitability, ETON's ROE is +0.40%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ETON is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ETON.Check TAK's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, HLN has a market cap of 44.4B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while HLN trades at $10.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas HLN's P/E ratio is 18.80. In terms of profitability, ETON's ROE is +0.40%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ETON is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ETON.Check HLN's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, TEVA has a market cap of 42B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while TEVA trades at $36.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas TEVA's P/E ratio is 12.30. In terms of profitability, ETON's ROE is +0.40%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ETON is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for ETON.Check TEVA's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ZTS has a market cap of 32.4B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ZTS trades at $77.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ZTS's P/E ratio is 11.74. In terms of profitability, ETON's ROE is +0.40%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, ETON is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ZTS's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, VTRS has a market cap of 19.4B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while VTRS trades at $16.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas VTRS's P/E ratio is 6.60. In terms of profitability, ETON's ROE is +0.40%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ETON is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ETON.Check VTRS's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ETON's ROE is +0.40%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ETON is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ITCI's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ELAN has a market cap of 11.9B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ELAN trades at $23.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ELAN's P/E ratio is 22.56. In terms of profitability, ETON's ROE is +0.40%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ETON is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ELAN's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ETON's ROE is +0.40%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ETON is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ETON.Check CTLT's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, RDY has a market cap of 10.1B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while RDY trades at $12.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas RDY's P/E ratio is 19.93. In terms of profitability, ETON's ROE is +0.40%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ETON is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ETON.Check RDY's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ALKS has a market cap of 7.9B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ALKS trades at $47.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ALKS's P/E ratio is 49.68. In terms of profitability, ETON's ROE is +0.40%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ETON is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ALKS's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while LNTH trades at $100.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas LNTH's P/E ratio is 16.95. In terms of profitability, ETON's ROE is +0.40%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ETON is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ETON.Check LNTH's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while AMRX trades at $17.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas AMRX's P/E ratio is 19.64. In terms of profitability, ETON's ROE is +0.40%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ETON is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for ETON.Check AMRX's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, INDV has a market cap of 4.3B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while INDV trades at $34.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas INDV's P/E ratio is 9.47. In terms of profitability, ETON's ROE is +0.40%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ETON is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for ETON.Check INDV's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ALVOW trades at $0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ALVOW's P/E ratio is 47.36. In terms of profitability, ETON's ROE is +0.40%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, ETON is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for ETON.Check ALVOW's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while RGC trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas RGC's P/E ratio is -387.32. In terms of profitability, ETON's ROE is +0.40%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ETON is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for ETON.Check RGC's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while SUPN trades at $43.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas SUPN's P/E ratio is 14.29. In terms of profitability, ETON's ROE is +0.40%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ETON is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for ETON.Check SUPN's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while BHC trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas BHC's P/E ratio is 1.65. In terms of profitability, ETON's ROE is +0.40%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ETON is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for ETON.Check BHC's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ETON's ROE is +0.40%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ETON is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ETON.Check DCPH's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ETON's ROE is +0.40%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ETON is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ETON.Check AVDL's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while HCM trades at $11.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas HCM's P/E ratio is 4.46. In terms of profitability, ETON's ROE is +0.40%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ETON is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for ETON.Check HCM's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while TRLV trades at $11.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas TRLV's P/E ratio is -4.78. In terms of profitability, ETON's ROE is +0.40%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, ETON is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for ETON.Check TRLV's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while PRGO trades at $14.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas PRGO's P/E ratio is 5.77. In terms of profitability, ETON's ROE is +0.40%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ETON is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for ETON.Check PRGO's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ETON's ROE is +0.40%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ETON is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ETON.Check EMBCV's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ETON's ROE is +0.40%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ETON is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ETON.Check DVAX's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ALVO trades at $5.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ALVO's P/E ratio is -15.41. In terms of profitability, ETON's ROE is +0.40%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, ETON is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for ETON.Check ALVO's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ANIP trades at $71.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ANIP's P/E ratio is 8.75. In terms of profitability, ETON's ROE is +0.40%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ETON is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for ETON.Check ANIP's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas TARO's P/E ratio is 30.05. In terms of profitability, ETON's ROE is +0.40%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ETON is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ETON.Check TARO's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while PAHC trades at $38.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas PAHC's P/E ratio is 13.10. In terms of profitability, ETON's ROE is +0.40%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ETON is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for ETON.Check PAHC's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while HROW trades at $36.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas HROW's P/E ratio is -37.34. In terms of profitability, ETON's ROE is +0.40%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ETON is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for ETON.Check HROW's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while CRON trades at $3.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas CRON's P/E ratio is 32.10. In terms of profitability, ETON's ROE is +0.40%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ETON is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for ETON.Check CRON's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while PCRX trades at $26.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas PCRX's P/E ratio is 10.18. In terms of profitability, ETON's ROE is +0.40%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ETON is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ETON.Check PCRX's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, AMPH has a market cap of 1B. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while AMPH trades at $22.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas AMPH's P/E ratio is 7.84. In terms of profitability, ETON's ROE is +0.40%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ETON is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for ETON.Check AMPH's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ETON's ROE is +0.40%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ETON is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ETON.Check PETQ's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, COLL has a market cap of 778.4M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while COLL trades at $24.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas COLL's P/E ratio is 3.01. In terms of profitability, ETON's ROE is +0.40%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ETON is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for ETON.Check COLL's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, IRWD has a market cap of 702.9M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while IRWD trades at $4.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas IRWD's P/E ratio is 5.47. In terms of profitability, ETON's ROE is +0.40%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ETON is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for ETON.Check IRWD's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, GLAS has a market cap of 657.7M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while GLAS trades at $8.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas GLAS's P/E ratio is -15.18. In terms of profitability, ETON's ROE is +0.40%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, ETON is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for ETON.Check GLAS's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, AQST has a market cap of 657.4M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while AQST trades at $5.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas AQST's P/E ratio is -8.06. In terms of profitability, ETON's ROE is +0.40%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ETON is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for ETON.Check AQST's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, EVO has a market cap of 639.4M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while EVO trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas EVO's P/E ratio is -2.54. In terms of profitability, ETON's ROE is +0.40%, compared to EVO's ROE of -0.27%. Regarding short-term risk, ETON is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for ETON.Check EVO's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, EOLS has a market cap of 598M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while EOLS trades at $9.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas EOLS's P/E ratio is -28.75. In terms of profitability, ETON's ROE is +0.40%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ETON is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ETON.Check EOLS's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ETON's ROE is +0.40%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ETON is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ETON.Check BDSI's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, TLRY has a market cap of 503.2M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while TLRY trades at $4.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas TLRY's P/E ratio is -4.15. In terms of profitability, ETON's ROE is +0.40%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ETON is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for ETON.Check TLRY's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, KMDA has a market cap of 483.5M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while KMDA trades at $8.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas KMDA's P/E ratio is 22.05. In terms of profitability, ETON's ROE is +0.40%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ETON is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for ETON.Check KMDA's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, CGC has a market cap of 411.6M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while CGC trades at $0.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas CGC's P/E ratio is -0.59. In terms of profitability, ETON's ROE is +0.40%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ETON is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for ETON.Check CGC's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, TKNO has a market cap of 379.6M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while TKNO trades at $7.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas TKNO's P/E ratio is -22.84. In terms of profitability, ETON's ROE is +0.40%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ETON is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ETON.Check TKNO's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, EBS has a market cap of 320.9M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while EBS trades at $6.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas EBS's P/E ratio is 4.32. In terms of profitability, ETON's ROE is +0.40%, compared to EBS's ROE of -0.36%. Regarding short-term risk, ETON is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for ETON.Check EBS's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ETON's ROE is +0.40%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ETON is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ALIM's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ETON's ROE is +0.40%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ETON is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for ETON.Check LNDC's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ACB has a market cap of 250.9M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ACB trades at $4.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ACB's P/E ratio is -8.27. In terms of profitability, ETON's ROE is +0.40%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ETON is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ACB's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, CRDL has a market cap of 247.8M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while CRDL trades at $2.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas CRDL's P/E ratio is -8.57. In terms of profitability, ETON's ROE is +0.40%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, ETON is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for ETON.Check CRDL's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, SIGA has a market cap of 232.4M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while SIGA trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas SIGA's P/E ratio is 12.00. In terms of profitability, ETON's ROE is +0.40%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ETON is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for ETON.Check SIGA's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ETON's ROE is +0.40%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ETON is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for ETON.Check TYHT's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ORGO has a market cap of 209.7M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ORGO trades at $1.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ORGO's P/E ratio is 54.33. In terms of profitability, ETON's ROE is +0.40%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, ETON is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ETON.Check ORGO's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, DERM has a market cap of 208.3M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while DERM trades at $7.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas DERM's P/E ratio is -20.46. In terms of profitability, ETON's ROE is +0.40%, compared to DERM's ROE of -0.20%. Regarding short-term risk, ETON is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for ETON.Check DERM's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas REPH's P/E ratio is -8.04. In terms of profitability, ETON's ROE is +0.40%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ETON is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for ETON.Check REPH's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, OGI has a market cap of 166.1M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while OGI trades at $1.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas OGI's P/E ratio is 2.65. In terms of profitability, ETON's ROE is +0.40%, compared to OGI's ROE of +0.21%. Regarding short-term risk, ETON is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for ETON.Check OGI's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, LFCR has a market cap of 164.7M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while LFCR trades at $4.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas LFCR's P/E ratio is -4.10. In terms of profitability, ETON's ROE is +0.40%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, ETON is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for ETON.Check LFCR's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas THTX's P/E ratio is -28.83. In terms of profitability, ETON's ROE is +0.40%, compared to THTX's ROE of +0.17%. Regarding short-term risk, ETON is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ETON.Check THTX's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ETON's ROE is +0.40%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ETON is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ASRT's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ETON's ROE is +0.40%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ETON is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ETON.Check SCTL's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, BGM has a market cap of 103.9M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while BGM trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas BGM's P/E ratio is -0.94. In terms of profitability, ETON's ROE is +0.40%, compared to BGM's ROE of -0.05%. Regarding short-term risk, ETON is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for ETON.Check BGM's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas PROC's P/E ratio is 1.53. In terms of profitability, ETON's ROE is +0.40%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ETON is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ETON.Check PROC's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, CPIX has a market cap of 98.3M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while CPIX trades at $6.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas CPIX's P/E ratio is -16.40. In terms of profitability, ETON's ROE is +0.40%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ETON is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for ETON.Check CPIX's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ETON's ROE is +0.40%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ETON is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ETON.Check OPTN's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ETON's ROE is +0.40%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ETON is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for ETON.Check ZOM's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ETON's ROE is +0.40%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, ETON is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ETON.Check GRVI's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ZYBT has a market cap of 78.2M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ZYBT trades at $1.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ZYBT's P/E ratio is -7.50. In terms of profitability, ETON's ROE is +0.40%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ETON is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for ETON.Check ZYBT's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ETON's ROE is +0.40%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ETON is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for ETON.Check ZYNE's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ETON's ROE is +0.40%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ETON is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for ETON.Check SSIC's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, INCR has a market cap of 65.3M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while INCR trades at $5.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas INCR's P/E ratio is -12.72. In terms of profitability, ETON's ROE is +0.40%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ETON is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for ETON.Check INCR's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ETON's ROE is +0.40%, compared to VLNS's ROE of N/A. Regarding short-term risk, ETON is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for ETON.Check VLNS's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, TLPH has a market cap of 61.2M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while TLPH trades at $1.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas TLPH's P/E ratio is -3.81. In terms of profitability, ETON's ROE is +0.40%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, ETON is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for ETON.Check TLPH's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ETON's ROE is +0.40%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ETON is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ETON.Check DRRX's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ETON's ROE is +0.40%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, ETON is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ETON.Check JUPW's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas QLI's P/E ratio is -4.92. In terms of profitability, ETON's ROE is +0.40%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ETON is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ETON.Check QLI's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, CPHI has a market cap of 35.8M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while CPHI trades at $0.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas CPHI's P/E ratio is -2.06. In terms of profitability, ETON's ROE is +0.40%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, ETON is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for ETON.Check CPHI's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, RMTI has a market cap of 32.2M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while RMTI trades at $8.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas RMTI's P/E ratio is -6.10. In terms of profitability, ETON's ROE is +0.40%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, ETON is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ETON.Check RMTI's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ETON's ROE is +0.40%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ETON is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for ETON.Check HEXO's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, TXMD has a market cap of 25.1M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while TXMD trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas TXMD's P/E ratio is 110.55. In terms of profitability, ETON's ROE is +0.40%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ETON is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for ETON.Check TXMD's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, AYTU has a market cap of 24.1M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while AYTU trades at $2.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas AYTU's P/E ratio is -1.17. In terms of profitability, ETON's ROE is +0.40%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, ETON is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for ETON.Check AYTU's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ETON's ROE is +0.40%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ETON is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ETON.Check CYTH's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ETON's ROE is +0.40%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ETON is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ETON.Check EVOK's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, OPTH has a market cap of 16.1M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while OPTH trades at $4.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas OPTH's P/E ratio is -18.26. In terms of profitability, ETON's ROE is +0.40%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, ETON is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for ETON.Check OPTH's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ETON's ROE is +0.40%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, ETON is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ETON.Check ACRX's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, CABR has a market cap of 12.4M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while CABR trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas CABR's P/E ratio is -2.43. In terms of profitability, ETON's ROE is +0.40%, compared to CABR's ROE of -3.86%. Regarding short-term risk, ETON is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for ETON.Check CABR's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ETON's ROE is +0.40%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ETON is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for ETON.Check AGRX's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ETON's ROE is +0.40%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ETON is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for ETON.Check NLTX's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas LCI's P/E ratio is -0.04. In terms of profitability, ETON's ROE is +0.40%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ETON is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ETON.Check LCI's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ETON's ROE is +0.40%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ETON is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for ETON.Check ADMP's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, YCBD has a market cap of 5.2M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while YCBD trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas YCBD's P/E ratio is -1.22. In terms of profitability, ETON's ROE is +0.40%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ETON is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ETON.Check YCBD's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while GELS trades at $0.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas GELS's P/E ratio is -1.08. In terms of profitability, ETON's ROE is +0.40%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ETON is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for ETON.Check GELS's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas MNK's P/E ratio is -0.44. In terms of profitability, ETON's ROE is +0.40%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ETON is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ETON.Check MNK's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ETON's ROE is +0.40%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ETON is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ETON.Check FLGC's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, SBFM has a market cap of 2.7M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while SBFM trades at $1.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas SBFM's P/E ratio is -0.19. In terms of profitability, ETON's ROE is +0.40%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, ETON is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for ETON.Check SBFM's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, RDHL has a market cap of 2.7M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while RDHL trades at $0.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas RDHL's P/E ratio is 0.17. In terms of profitability, ETON's ROE is +0.40%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, ETON is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for ETON.Check RDHL's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, UPC has a market cap of 2.7M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while UPC trades at $4.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas UPC's P/E ratio is -0.53. In terms of profitability, ETON's ROE is +0.40%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ETON is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for ETON.Check UPC's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ETON's ROE is +0.40%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ETON is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ETON.Check PLXP's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ETON's ROE is +0.40%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ETON is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ATNX's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while SNOA trades at $1.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas SNOA's P/E ratio is -1.09. In terms of profitability, ETON's ROE is +0.40%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, ETON is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for ETON.Check SNOA's competition here

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ETON stands at 1.7B. In comparison, SHPH has a market cap of 2.1M. Regarding current trading prices, ETON is priced at $60.43 on the NASDAQ, while SHPH trades at $3.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ETON currently has a P/E ratio of 131.37, whereas SHPH's P/E ratio is -0.17. In terms of profitability, ETON's ROE is +0.40%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, ETON is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ETON.Check SHPH's competition here